Metabolic / GLP-1 Agonist Research Peptides Guide
In-depth research guide covering 6 peptides in the Metabolic / GLP-1 Agonist category. Includes evidence ratings, mechanisms, and clinical status for each compound.
Overview
This guide covers 6 research peptides in the Metabolic / GLP-1 Agonist category. Each compound is evaluated on its evidence base, mechanism, safety profile, and current clinical status.
Semaglutide — FDA Approved
Evidence: A | Status: FDA-approved (Ozempic for T2D, Wegovy for obesity)
Semaglutide is an FDA-approved GLP-1 receptor agonist (MW ~4113.6 g/mol, molecular formula C187H291N45O59) with 94% sequence homology to human GLP-1.
Use cases: Weight Management, Metabolic Health, Cardiovascular
Liraglutide — FDA Approved
Evidence: A | Status: FDA-approved (Victoza for T2D, Saxenda for obesity)
Liraglutide is an FDA-approved GLP-1 receptor agonist with 97% amino acid sequence homology to endogenous human GLP-1. Developed by Novo Nordisk, it is approved as Victoza for type 2 diabetes and Saxenda for chronic weight management.
Use cases: Weight Management, Metabolic Health, Cardiovascular
Exenatide — FDA Approved
Evidence: A | Status: FDA-approved (Byetta for T2D, 2005; Bydureon for T2D, 2012)
Exenatide is a 39-amino-acid GLP-1 receptor agonist (MW ~4186.6 g/mol) originally derived from exendin-4, a peptide found in the saliva of the Gila monster (Heloderma suspectum).
Use cases: Metabolic Health, Weight Management
Dulaglutide — FDA Approved
Evidence: A | Status: FDA-approved (Trulicity for T2D, September 2014; cardiovascular risk reduction, 2020)
Dulaglutide (brand name Trulicity) is a once-weekly GLP-1 receptor agonist developed by Eli Lilly, FDA-approved in September 2014 for type 2 diabetes.
Use cases: Metabolic Health, Cardiovascular
Lixisenatide — FDA Approved
Evidence: A | Status: FDA-approved (Adlyxin for T2D, July 2016; Soliqua 100/33 combination, November 2016)
Lixisenatide is a once-daily GLP-1 receptor agonist (MW ~4858.5 g/mol) based on the exendin-4 scaffold, with a modified C-terminal tail containing six lysine residues.
Use cases: Metabolic Health
Albiglutide — FDA Approved
Evidence: A | Status: Previously FDA-approved (Tanzeum for T2D, April 2014). Voluntarily withdrawn from market July 2018 (commercial reasons, not safety).
Albiglutide (brand name Tanzeum in the US, Eperzan in Europe) was a once-weekly GLP-1 receptor agonist consisting of two copies of a modified GLP-1 sequence fused to human albumin (MW ~72,970 g/mol).
Use cases: Metabolic Health, Cardiovascular
Shop Research Peptides
Semaglutide 10mg
10mg
Retatrutide 20mg
20mg
BPC-157 5mg
5mg
Ipamorelin 10mg
10mg
TB-500 5mg
5mg
Retatrutide 10mg
10mg
GHK-Cu 50mg
50mg
Sermorelin 5mg
5mg
Tesamorelin 10mg
10mg
Quality Documentation
Review batch documentation before making research purchasing decisions. Volta pairs product education with COA literacy so researchers can evaluate purity, identity, lot details, and testing context.
Product cards on this page link to current catalog entries and available quality documentation.
Related Research News
Semaglutide News: Orthopedic Surgeon Shares Key Insights on Ozempic and Wegovy
Recent semaglutide news highlights an orthopedic surgeon's perspective on Ozempic and Wegovy. The report touches on weight loss efficacy and safety considerations, offering context for researchers and industry professionals tracking GLP-1 developments.
Semaglutide News: Novo Nordisk's GLP-1 Lead Faces New Challenges
Recent semaglutide news highlights how Novo Nordisk's early lead in GLP-1 weight-loss drugs is being tested. This analysis covers the company's position, the science behind semaglutide, and what researchers should watch next.
Semaglutide News: Novo Nordisk Wins Dutch Patent Injunction
Novo Nordisk has secured a Dutch court injunction in a semaglutide patent infringement case, according to recent reports. The decision adds a layer of legal protection for the drug, which is also marketed as Wegovy. This semaglutide news highlights ongoing efforts to safeguard intellectual property in the growing GLP-1 market.
Peptide Tools
Follow Research Updates
Get new research pages, product updates, tool releases, and quality resources from Volta.
Subscribe